Tango Therapeutics, Inc. — Form 8-K/A
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 52/100
What the filing says
Dr. Barbara Weber, Executive Chairman, was terminated without cause effective August 3, 2026. Severance includes: base salary continuation through December 31, 2026; employer-paid COBRA premiums through end-2026; full acceleration of all unvested RSUs and stock options; extended stock option exercise period to August 3, 2027; and pro-rata 2026 bonus. Weber resigned from all board and officer positions. Standard restrictive covenants apply (1-year non-compete, confidentiality, non-disparagement).
Why this rating
Material leadership change (Executive Chair departure) relative to ~$528M market cap, but orderly transition with clear succession (CEO Malte Peters already in place). Equity acceleration is significant internally but details/value not disclosed. No major operational, financial, or strategic disruption evident.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.